nCounter® Gene Fusion Panels and CNV Assays
Helping Your Research
Increasing numbers of actionable fusions have made traditional technologies such as PCR and FISH inefficient and costly. NGS can profile multiple fusions in a single assay but is slow, complex, and expensive. Combined with direct digital counting on the nCounter system and Junction Sequence probe design, the detection of fusion genes is highly sensitive, quantitative, and easy:
- Directly detect hundreds of fusions in one assay
- Gets results in less than 24 hrs with just 15 minutes of hands-on time
- Use challenging sample types including FFPE tissue sections
- Multiplex at the price of single-plex assays
How it Works
nCounter CNV Assays: direct and robust CNV detection with a simple workflow
Abberations in copy number are implicated in many diseases, from genetic disorders to cancer. FISH has traditionally been used to detect CNVs, but the growing number and importance of CNVs has made higher-plex technologies such as microarrays and NGS more attractive. However, these approaches require cumbersome and time-consuming workflows and a significant amount of expertise. Additionally, most microarrays are not able to resolve CNVs from FFPE samples.
NanoString’s nCounter technology makes it easy to directly quantify CNVs from up to 800 loci with:
- Robust performance on FFPE
- A simple assay that doesn’t require expertise
- Minimal hands-on time and fast time-to-results
- Lower cost than FFPE microarray assays or NGS
Additionally, the nCounter v2 Cancer Copy Number Assay offers an off-the-shelf option for multiplexed quantification of 87 genes commonly amplified or deleted in cancer including PIK3CA, AKT, PTEN, BRCA, ERBB2, and MYC.
- Optimized for FFPE samples
- Copy number analysis of 87 genes commonly amplified or deleted in cancer
- Digital quantitation of highly amplified genes
- Specific detection of bi-allelic and multi-allelic number of copies
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
The Vantage 3D™ Lung Fusion Panel includes 63 probes: 35 for specific fusion detection, 24 for positional gene expression imbalance detection, and 4 internal reference genes. Specific Lung Gene Fusion Probes detect the following gene fusion families:
Lung imbalance probes detect gene expression imbalance in the following genes:
The Vantage 3D Leukemia Fusion Panel includes 42 probes in total: 27 for specific fusion detection, 12 leukemia genes, and 3 internal reference genes.
Leukemia Gene Fusion Probes detect the following gene fusion families:
Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma.
BACKGROUND: Gastroesophageal adenocarcinoma (GOA) has poor clinical outcomes and lacks reliable blood markers. Here we present circulating tumour DNA (ctDNA) as an emerging biomarker.
Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes
Ovarian cancer comprises multiple subtypes (clear-cell (CCC), endometrioid (EC), high-grade serous (HGSC), low-grade serous (LGSC), and mucinous carcinomas (MC)) with differing molecular and clinical behavior. However, robust histotype-specific biomarkers for clinical use have yet to be identified.
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Breast cancer is the most commonly occurring cancer in women. There were over two-million new cases in world in 2018.